10-K: Eyenovia Faces Going Concern Doubts Amid Strategic Review and MicroPine Setback

Eyenovia is exploring strategic alternatives and cutting costs after a negative clinical trial result, raising concerns about its ability to continue as a going concern.

Summary

• Eyenovia, Inc., an ophthalmic technology company, faces substantial doubt about its ability to continue as a going concern due to operating losses and the need for additional capital.
• The company is exploring strategic alternatives, including a potential business combination, reverse merger, or asset sales, after a negative Phase III clinical trial result for MicroPine.
• Eyenovia has paused the national sales roll-out of clobetasol propionate and Mydcombi pending additional funding.
• The company is focusing on Optejet Gen-2 development and dry eye collaborations.
• A reduction in force affecting approximately 75% of the workforce has been implemented to minimize expenses, with severance-related expenses estimated at $0.3 million.
• Eyenovia is progressing with the development of the Optejet UFD, aiming for a 510K submission in the United States in the fourth quarter of 2025.
• The company has entered into a non-binding letter of intent with Betaliq for a potential business combination, which could result in Betaliq stockholders owning approximately 83.7% of the combined company.
• As of December 31, 2024, Eyenovia had cash and cash equivalents of $2.1 million and an accumulated deficit of $195.3 million.
• The company owed $10.2 million in principal and accrued interest under a loan and security agreement as of March 15, 2025.
• Eyenovia has regained compliance with Nasdaq's minimum bid price requirement following a 1-for-80 reverse stock split.

Sentiment

Score: 3

Explanation: The document presents a concerning financial outlook for Eyenovia, with significant risks and uncertainties surrounding its ability to continue as a going concern. The negative clinical trial result and subsequent restructuring further contribute to the negative sentiment.

Positives

• Eyenovia is actively exploring strategic alternatives to maximize shareholder value.
• The company is focusing on Optejet Gen-2 development, which has the potential to increase the value of the asset.
• Eyenovia has regained compliance with Nasdaq's minimum bid price requirement.
• The company has a non-binding collaboration agreement with Formosa to develop EYEN-530 for acute dry eye flare-ups.
• Avenue has agreed to defer principal and interest payments until the end of September 2025.

Negatives

• Eyenovia faces substantial doubt about its ability to continue as a going concern.
• The company has incurred significant operating losses and has a working capital deficit.
• A negative Phase III clinical trial result for MicroPine has led to a restructuring and cost-cutting measures.
• The proposed business combination with Betaliq may not be consummated on the terms described or at all.
• The company has paused the national sales roll-out of clobetasol propionate and Mydcombi pending additional funding.
• There is a risk of delisting from Nasdaq if the company fails to maintain compliance with listing rules.

Risks

• The company's ability to continue as a going concern is dependent on securing additional financing.
• The exploration of strategic alternatives may not result in a transaction or may not deliver anticipated benefits.
• Delisting from Nasdaq could prevent the company from maintaining an active trading market for its common stock.
• The company may be unable to comply with the terms of the loan modification agreement with Avenue.
• The proposed business combination with Betaliq may not be consummated or may not be favorable to Eyenovia stockholders.
• The company is subject to ongoing regulatory obligations and continued regulatory review of its products.
• The company is highly dependent on its senior management team.
• The company may encounter delays in the manufacturing of the second generation Optejet device.
• The company's success depends on its ability to protect its intellectual property.
• The price of the company's common stock has been and may continue to be volatile.

Future Outlook

Eyenovia is exploring strategic business options intended to maximize shareholder value, including the potential commercialization of Mydcombi and clobetasol propionate and completing the development of its Optejet device. The company aims to become a leading developer and licensor of the Optejet in multiple formats, beginning with the UFD, then adding device-drug combinations and a digital health platform for improved patient care outcomes.

Management Comments

• Management plans concerning the need to raise additional capital are described in Note 2 Summary of Significant Accounting Policies Liquidity and Going Concern of our financial statements included within this Annual Report on Form 10-K.

Industry Context

The biotechnology and pharmaceutical industries are characterized by rapidly advancing technologies, intense competition, and a strong emphasis on proprietary products. Eyenovia faces potential competition from large pharmaceutical and biotechnology companies, specialty pharmaceutical and generic or biosimilar drug companies.

Comparison to Industry Standards

• The document does not provide enough information to make a detailed comparison to industry standards.
• To perform a comparison, specific benchmarks related to ophthalmic technology companies, clinical trial success rates, and financial performance metrics would be needed.
• Comparable companies in the ophthalmic space include Alcon, Bausch + Lomb, and Novartis (Alcon division), but a direct comparison requires more detailed financial and operational data.

Related Party Transactions

• The company has a license agreement with Arctic Vision, which is considered a related party transaction.
• The company has a license agreement with Senju, which is owned by the family of a former member of the company's Board of Directors.
• The company has an advisory agreement with Dr. Ianchulev, a member of the company's Board of Directors.

Stakeholder Impact

• Shareholders face the risk of losing their investment if the company is unable to continue as a going concern.
• Employees have been affected by the reduction in force.
• Customers may experience disruptions in the availability of Mydcombi and clobetasol propionate.
• Suppliers and creditors face increased risk due to the company's financial instability.

Next Steps

• Eyenovia will continue to assess a full range of strategic alternatives, including but not limited to, a business combination, sale of the Company, reverse merger, asset sale, or a combination of alternatives, while also carefully managing its expenses.
• The Company will focus its development efforts on completing the verification and validation studies required for regulatory approval of the Optejet UFD.
• The parties intend to negotiate a definitive business combination agreement consistent with the provisions of the Letter of Intent as well as other terms and conditions typical for transactions of this nature.

Key Dates

Keywords

Eyenovia, strategic alternatives, going concern, MicroPine, Optejet, Betaliq, clinical trial, financing, Nasdaq, Mydcombi, clobetasol propionate